Matrix metalloproteinase-2, -9, -12, and tissue inhibitor of metalloproteinase 2 gene polymorphisms and cutaneous expressions in patients with Behçet's disease

Tissue Antigens

Volumn 79, Issue 5, 2012, Pages 333-339

  Park, K S ^a   Min, Y ^a   Park, S R ^a   Kim, E H ^b   Lee, D J ^c   Bang, D ^d   Lee, E S ^c  

^a Sungshin Women's University   (South Korea)

^b Kwandong University College of Medicine   (South Korea)

^c Ajou University School of Medicine   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

Author keywords

Beh et's disease; Matrix metalloproteinase 2, 9, 12; Tissue inhibitors of metalloproteinase 2

Indexed keywords

GELATINASE A; GELATINASE B; MACROPHAGE ELASTASE; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADOLESCENT; ADULT; AGED; ARTICLE; BEHCET DISEASE; CONTROLLED STUDY; DNA POLYMORPHISM; ERYTHEMA NODOSUM; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SKIN;

ADOLESCENT; ADULT; AGED; ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; BEHCET SYNDROME; CASE-CONTROL STUDIES; ERYTHEMA NODOSUM; FEMALE; GENOTYPE; HAPLOTYPES; HUMANS; MALE; MATRIX METALLOPROTEINASE 12; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROMOTER REGIONS, GENETIC; REPUBLIC OF KOREA; SKIN; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 84862799512     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/j.1399-0039.2012.01863.x     Document Type: Article

References (25)

1. Keogan MT. Clinical immunology review series: an approach to the patient with recurrent orogenital ulceration, including Behçet's syndrome. Clin Exp Immunol 2009: 156: 1-11.
2. Lee S, Bang D, Lee ES, Sohn S. Behçet's disease: A Guide to Its Clinical Understanding, Berlin, Heidelberg: Springer-Verlag, 2001:19-50.
3. de Chambrun MP, Wechsler B, Geri G, Cacoub P, Saadoun D. New insights into the pathogenesis of Behçet's disease. Autoimmun Rev 2011 [Epub ahead of print].
4. Durmazlar SP, Ulkar GB, Eskioglu F, Tatlican S, Mert A, Akgul A. Significance of serum interleukin-8 levels in patients with Behçet's disease: high levels may indicate vascular involvement. Int J Dermatol 2009: 48: 259-64.
5. Price SJ, Greaves DR, Watkins H. Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J Biol Chem 2001: 276: 7549-58.
6. Zhang B, Ye S, Herrmann SM et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 1999: 99: 1788-94.
7. Chen D, Wang Q, Ma ZW et al. MMP-2, MMP-9 and TIMP-2 gene polymorphisms in Chinese patients with generalized aggressive periodontitis. J Clin Periodontol 2007: 34: 384-9.
8. Hamzaoui K, Maitre B, Hamzaoui A. Elevated levels of MMP-9 and TIMP-1 in the cerebrospinal fluid of neuro-Behçet's disease. Clin Exp Rheumatol 2009: 27: S52-7.
9. Lee YJ, Kang SW, Baek HJ et al. Association between matrix metalloproteinase 9 promoter polymorphisms and Behçet's disease. Hum Immunol 2010: 71: 717-22.
10. Pay S, Abbasov T, Erdem H et al. Serum MMP-2 and MMP-9 in patients with Behçet's disease: do their higher levels correlate to vasculo-Behçet's disease associated with aneurysm formation? Clin Exp Rheumatol 2007: 25: S70-5.
11. Van Lint P, Libert C. Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation. J Leukoc Biol 2007: 82: 1375-81.
12. Adair-Kirk TL, Senior RM. Fragments of extracellular matrix as mediators of inflammation. Int J Biochem Cell Biol 2008: 40: 1101-10.
13. Manicone AM, McGuire JK. Matrix metalloproteinases as modulators of inflammation. Semin Cell Dev Biol 2008: 19: 34-41.
14. Butler GS, Overall CM. Updated biological roles for matrix metalloproteinases and new "intracellular" substrates revealed by degradomics. Biochemistry 2009: 48: 10830-45.
15. Garg P, Vijay-Kumar M, Wang L, Gewirtz AT, Merlin D, Sitaraman SV. Matrix metalloproteinase-9-mediated tissue injury overrides the protective effect of matrix metalloproteinase-2 during colitis. Am J Physiol Gastrointest Liver Physiol 2009: 296: G175-84.
16. Shipley JM, Wesselschmidt RL, Kobayashi DK, Ley TJ, Shapiro SD. Metalloelastase is required for macrophage-mediated proteolysis and matrix invasion in mice. Proc Natl Acad Sci U S A 1996: 93: 3942-6.
17. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006: 69: 562-73.
18. Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease. Lancet 1990: 335: 1078-80.
19. Harendza S, Lovett DH, Panzer U, Lukacs Z, Kuhnl P, Stahl RA. Linked common polymorphisms in the gelatinase a promoter are associated with diminished transcriptional response to estrogen and genetic fitness. J Biol Chem 2003: 278: 20490-9.
20. De Clerck YA, Darville MI, Eeckhout Y, Rousseau GG. Characterization of the promoter of the gene encoding human tissue inhibitor of metalloproteinases-2 (TIMP-2). Gene 1994: 139: 185-91.
21. Wang F, Jin XP, Zhu M et al. Genotype association of C(-735)T polymorphism of the MMP-2 gene with the risk of carotid atherosclerosis-vulnerable plaque in the Han Chinese population. Vasc Med 2011: 16: 13-8.
22. Yi SW, Kim EH, Kang HY, Kim YC, Lee ES. Erythema nodosum: clinicopathologic correlations and their use in differential diagnosis. Yonsei Med J 2007: 48: 601-8.
23. Aksoy Y, Ercan A, Dalmizrak O, Canpinar H, Kartal Durmazlar SP, Bayazit M. The determination of matrix metalloproteinase 9 activity and gene expression levels in Behçet's disease patients with aneurysmal complications. Clin Rheumatol 2011: 30: 515-9.
24. Marzano AV, Cugno M, Trevisan V et al. Role of inflammatory cells, cytokines and matrix metalloproteinases in neutrophil-mediated skin diseases. Clin Exp Immunol 2010: 162: 100-7.
25. Parks WC, Wilson CL, Lopez-Boado YS. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 2004: 4: 617-29.